Swedish - First Hill Campus
Seattle, WA
Accepting patients
Iberdomide vs. Observation Post Ide-Cel CAR-T
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
- CELMoD
- Maintenance
- Randomization
- Phase 2
Not yet accepting
DURGA-4
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- CAR T Cell
- CD19
- BCMA
- Randomization
- Phase 3
Accepting patients
Triplet Induction + 1 or 2-Drug Maintenance
A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
- Monoclonal Antibody
- CD38
- Randomization
- Maintenance
- Phase 3
Not currently accepting
EQUATE
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Monoclonal Antibody
- CD38
- Phase 3
Accepting patients
Early Detection Blood Tests
Blinded Reference Set for Multicancer Early Detection Blood Tests
- Observational Trial